Dr. Nathan Gossai, MD
Claim this profileChildren's Hospital and Clinics of Minnesota
Studies Leukemia
Studies Acute Myeloid Leukemia
6 reported clinical trials
17 drugs studied
Affiliated Hospitals
Clinical Trials Nathan Gossai, MD is currently running
Caloric Restriction + Activity
for Acute Lymphoblastic Leukemia
This trial tests if a personalized diet and exercise plan can help older children, adolescents, and young adults with high-risk B-cell Acute Lymphoblastic Leukemia respond better to chemotherapy. The plan aims to reduce body fat, which is linked to treatment resistance, and limit fat gain during chemotherapy.
Recruiting1 award Phase 2
Tagraxofusp
for Blood Cancers
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Recruiting1 award Phase 1
More about Nathan Gossai, MD
Clinical Trial Related9 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Nathan Gossai, MD has experience with
- Matched Targeted Therapy
- 2-chlorodeoxyadenosine
- Cytosine Arabinoside
- Hematopoietic Stem Cell Transplantation (RIC-HSCT)
- INDOMETHACIN
- Intravenous Immunoglobulin
Breakdown of trials Nathan Gossai, MD has run
Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Relapse
Matched Targeted Therapy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nathan Gossai, MD specialize in?
Nathan Gossai, MD focuses on Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Leukemia has involved CD123 positive patients, or patients who are undergoing treatment.
Is Nathan Gossai, MD currently recruiting for clinical trials?
Yes, Nathan Gossai, MD is currently recruiting for 3 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Nathan Gossai, MD has studied deeply?
Yes, Nathan Gossai, MD has studied treatments such as Matched Targeted Therapy, 2-chlorodeoxyadenosine, Cytosine Arabinoside.
What is the best way to schedule an appointment with Nathan Gossai, MD?
Apply for one of the trials that Nathan Gossai, MD is conducting.
What is the office address of Nathan Gossai, MD?
The office of Nathan Gossai, MD is located at: Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota 55404 United States. This is the address for their practice at the Children's Hospital and Clinics of Minnesota.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.